◀ Back to TP53
RAD17 — TP53
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Li et al., Oncogene 1999
(Fibrosarcoma) :
hRAD17 , a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene,
stimulates p53 accumulation ... Permanent overexpression of the
hRAD17 gene in human fibrosarcoma cells
resulted in
p53 activation and a significant reduction of S- and G2/M-phase cells accompanied by an accumulation of the G1-phase population, suggesting that hRAD17 may have a role in cell cycle checkpoint control
Tang et al., J Biol Chem 2002
:
In response to DNA damage, ataxia-telangiectasia mutant and ataxia-telangiectasia and
Rad-3 activate
p53 , resulting in either cell cycle arrest or apoptosis
Liu et al., Anticancer Res 2011
(Breast Neoplasms) :
The p53 pathway was involved in the synergism of RAD001 and carboplatin on breast cancer cell proliferation and apoptosis, since the synergistic effect was demonstrated in all tested breast cancer cell lines with wild-type p53 and the use of p53 inhibitor partially antagonized the
effect of
RAD001 and carboplatin on
p53 and p21 expression, as well as their inhibitory effect on cell proliferation
Ghosh et al., J Radiat Res 2012
(Neutropenia...) :
The results demonstrated that
Ex-RAD ameliorates radiation induced peripheral blood cell depletion, promotes bone marrow recovery,
reduces p53 signaling in spleen and protects intestine from radiation injury